newsfilter
← Latest News
GlobeNewswire·

Immatics Announces First Quarter 2025 Financial Results and Business Update

IMA203 PRAME Cell Therapy: Randomized-controlled Phase 3 trial, SUPRAME, in previously treated advanced melanoma ongoing and expected to complete enrollment in 2026IMA203 PRAME Cell Therapy: Phase 1b clinical trial